Clinical Trial Update: Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM [Phase 2]

View source ↗

Summary

Phase 2 study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-12-06